Mary Pinder-Schenck

2.7k total citations
14 papers, 452 citations indexed

About

Mary Pinder-Schenck is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Mary Pinder-Schenck has authored 14 papers receiving a total of 452 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 10 papers in Oncology and 5 papers in Molecular Biology. Recurrent topics in Mary Pinder-Schenck's work include Lung Cancer Treatments and Mutations (9 papers), Lung Cancer Research Studies (5 papers) and Lung Cancer Diagnosis and Treatment (4 papers). Mary Pinder-Schenck is often cited by papers focused on Lung Cancer Treatments and Mutations (9 papers), Lung Cancer Research Studies (5 papers) and Lung Cancer Diagnosis and Treatment (4 papers). Mary Pinder-Schenck collaborates with scholars based in United States, Italy and Taiwan. Mary Pinder-Schenck's co-authors include Alberto Chiappori, Jhanelle E. Gray, Tawee Tanvetyanon, Eric B. Haura, Gerold Bepler, Charles C. Williams, Xiuhua Zhao, Scott Antonia, Kristine A. Donovan and Kristin M. Phillips and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Mary Pinder-Schenck

14 papers receiving 447 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mary Pinder-Schenck United States 11 221 209 202 76 45 14 452
Rebecca Teng United States 7 184 0.8× 367 1.8× 107 0.5× 57 0.8× 107 2.4× 13 518
Charles Naltet France 11 226 1.0× 332 1.6× 65 0.3× 41 0.5× 120 2.7× 44 450
Hassan Fazilaty Iran 12 36 0.2× 183 0.9× 239 1.2× 92 1.2× 36 0.8× 25 405
Wendie Den Brok Canada 4 83 0.4× 168 0.8× 63 0.3× 86 1.1× 22 0.5× 6 260
María Ángeles Vaz Salgado Spain 9 101 0.5× 125 0.6× 81 0.4× 62 0.8× 22 0.5× 44 354
Ravindra Pramod Deshpande United States 11 76 0.3× 119 0.6× 232 1.1× 143 1.9× 98 2.2× 26 418
Yolanda Jerez Spain 12 83 0.4× 297 1.4× 123 0.6× 105 1.4× 11 0.2× 30 433
Aleksandra Łacko Poland 9 50 0.2× 179 0.9× 119 0.6× 90 1.2× 81 1.8× 41 298
Diego Márquez-Medina Spain 10 259 1.2× 308 1.5× 102 0.5× 44 0.6× 48 1.1× 26 462
Susana Sousa Portugal 9 90 0.4× 80 0.4× 113 0.6× 40 0.5× 7 0.2× 28 254

Countries citing papers authored by Mary Pinder-Schenck

Since Specialization
Citations

This map shows the geographic impact of Mary Pinder-Schenck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary Pinder-Schenck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary Pinder-Schenck more than expected).

Fields of papers citing papers by Mary Pinder-Schenck

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mary Pinder-Schenck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary Pinder-Schenck. The network helps show where Mary Pinder-Schenck may publish in the future.

Co-authorship network of co-authors of Mary Pinder-Schenck

This figure shows the co-authorship network connecting the top 25 collaborators of Mary Pinder-Schenck. A scholar is included among the top collaborators of Mary Pinder-Schenck based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mary Pinder-Schenck. Mary Pinder-Schenck is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Gray, Jhanelle E., Alberto Chiappori, Tawee Tanvetyanon, et al.. (2018). A phase I/randomized phase II study of GM.CD40L vaccine in combination with CCL21 in patients with advanced lung adenocarcinoma. Cancer Immunology Immunotherapy. 67(12). 1853–1862. 29 indexed citations
2.
Gopalan, Priya, Chunxia Cao, Mary Pinder-Schenck, et al.. (2018). CDK4/6 inhibition stabilizes disease in patients with p16-null non-small cell lung cancer and is synergistic with mTOR inhibition. Oncotarget. 9(100). 37352–37366. 31 indexed citations
3.
Choi, Clara Y.H., Heather A. Wakelee, Joel W. Neal, et al.. (2017). Vorinostat and Concurrent Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Brain Metastases: A Phase 1 Dose Escalation Trial. International Journal of Radiation Oncology*Biology*Physics. 99(1). 16–21. 13 indexed citations
4.
Scagliotti, Giorgio V., Jin Hyoung Kang, David C. Smith, et al.. (2016). Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer. Investigational New Drugs. 34(5). 625–635. 55 indexed citations
5.
Modlin, L.A., Changhoon Choi, Iris C. Gibbs, et al.. (2015). Vorinostat and Concurrent Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Brain Metastases: A Phase 1 Dose-Escalation Trial. International Journal of Radiation Oncology*Biology*Physics. 93(3). S178–S178. 1 indexed citations
6.
7.
Dilling, Thomas J., Martine Extermann, Jongphil Kim, et al.. (2014). Phase 2 Study of Concurrent Cetuximab Plus Definitive Thoracic Radiation Therapy Followed by Consolidation Docetaxel Plus Cetuximab in Poor Prognosis or Elderly Patients With Locally Advanced Non-Small Cell Lung Cancer. International Journal of Radiation Oncology*Biology*Physics. 90(4). 828–833. 10 indexed citations
8.
Pinder-Schenck, Mary, et al.. (2014). Systemic and Targeted Therapies for Early-Stage Lung Cancer. Cancer Control. 21(1). 21–31. 21 indexed citations
9.
10.
Gray, Jhanelle E., Eric B. Haura, Alberto Chiappori, et al.. (2014). A Phase I, Pharmacokinetic, and Pharmacodynamic Study of Panobinostat, an HDAC Inhibitor, Combined with Erlotinib in Patients with Advanced Aerodigestive Tract Tumors. Clinical Cancer Research. 20(6). 1644–1655. 46 indexed citations
11.
Bepler, Gerold, Charles C. Williams, Michael J. Schell, et al.. (2013). Randomized International Phase III Trial of ERCC1 and RRM1 Expression–Based Chemotherapy Versus Gemcitabine/Carboplatin in Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 31(19). 2404–2412. 108 indexed citations
12.
Martins, Renato, Thomas A. D’Amico, Billy W. Loo, et al.. (2012). The Management of Patients With Stage IIIA Non–Small Cell Lung Cancer With N2 Mediastinal Node Involvement. Journal of the National Comprehensive Cancer Network. 10(5). 599–613. 54 indexed citations
13.
Phillips, Kristin M., Heather Jim, Kristine A. Donovan, Mary Pinder-Schenck, & Paul B. Jacobsen. (2011). Characteristics and correlates of sleep disturbances in cancer patients. Supportive Care in Cancer. 20(2). 357–365. 46 indexed citations
14.
Pinder-Schenck, Mary & Gerold Bepler. (2009). Neoadjuvant chemotherapy for non-small cell lung cancer.. PubMed. 64(6). 611–28. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rebecca Teng Breakdown of academic impact, for papers by Charles Naltet Breakdown of academic impact, for papers by Hassan Fazilaty Breakdown of academic impact, for papers by Wendie Den Brok Breakdown of academic impact, for papers by María Ángeles Vaz Salgado Breakdown of academic impact, for papers by Ravindra Pramod Deshpande Breakdown of academic impact, for papers by Yolanda Jerez Breakdown of academic impact, for papers by Aleksandra Łacko Breakdown of academic impact, for papers by Diego Márquez-Medina Breakdown of academic impact, for papers by Susana Sousa
Rankless by CCL
2026